报报道，GenzmpeTransgenics公司和GenzpoeGeneral公司的重组人抗凝血酶利可影响用于进行冠脉旁路移植术（CABG）病人的肝素的抗凝血作用。在美国圣地亚哥召开的美国血液学协会年度会议上，该公司的研究者陈述了一项D期临床研究的结果。他们认为这是已成功完成的转基因产生的重 Reported that the recombinant human antithrombin available from GenzmpeTransgenics and Genzpoe General can affect the anticoagulant effect of heparin in patients undergoing coronary artery bypass grafting (CABG). At the annual meeting of the American Association of Hematology in San Diego, USA, researchers at the company presented the results of a Phase D clinical study. They think it is the genetically engineered weight that has been successfully completed